nach oben

Journal of Nuclear Cardiology

Erschienen in:

24.04.2020 | Editorial

¹⁸F-FDG PET imaging of myocardial inflammation and viability following experimental infarction and anti-inflammatory treatment with compound MCC950

verfasst von: Jeremy Jong, BS, René R. Sevag Packard, MD, PhD

Erschienen in: Journal of Nuclear Cardiology | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Excerpt

In this issue of the Journal of Nuclear Cardiology, Li and Yang et al. explore the role of ¹⁸F-fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging to assess myocardial inflammation and viability in the context of treatment with the anti-inflammatory molecule sulfonylurea MCC950 following acute myocardial infarction (AMI).1 The effect of MCC950, a NOD [nucleotide-binding and oligomerization domain]-like receptor pyrin domain-containing protein-3 (NLRP-3) inflammasome inhibitor, was assessed using various FDG PET protocols to image the myocardium following experimental ligation of the left main coronary artery and ensuing AMI in C57BL/6 adult male mice.2 MCC950 was administered immediately after surgery and daily for 7 days. Following surgery, FDG PET imaging was conducted to (i) quantify myocardial inflammation at days 3 and 5, and (ii) determine myocardial viability at days 7 and 28. Histology, immunohistochemistry, and Western blotting were used as reference standards and cardiac mechanical parameters were obtained by echocardiography. …

Li X, Yang W, Ma W, Zhou X, Quan Z, Li G, Liu D, Zhang Q, Han D, Gao B, Li C, Wang J, Kang F. (18)F-FDG PET imaging-monitored anti-inflammatory therapy for acute myocardial infarction: Exploring the role of MCC950 in murine model. J Nucl Cardiol 2020. https://doi.org/10.1007/s12350-020-02044-0.CrossRefPubMed

Gao E, Lei YH, Shang X, Huang ZM, Zuo L, Boucher M, Fan Q, Chuprun JK, Ma XL, Koch WJ. A novel and efficient model of coronary artery ligation and myocardial infarction in the mouse. Circ Res 2010;107:1445-53.CrossRef

Yan X, Anzai A, Katsumata Y, Matsuhashi T, Ito K, Endo J, Yamamoto T, Takeshima A, Shinmura K, Shen W, Fukuda K, Sano M. Temporal dynamics of cardiac immune cell accumulation following acute myocardial infarction. J Mol Cell Cardiol 2013;62:24-35.CrossRef

Fang L, Moore XL, Dart AM, Wang LM. Systemic inflammatory response following acute myocardial infarction. J Geriatr Cardiol 2015;12:305-12.PubMedPubMedCentral

Frangogiannis NG. The immune system and the remodeling infarcted heart: Cell biological insights and therapeutic opportunities. J Cardiovasc Pharmacol 2014;63:185-95.CrossRef

Westman PC, Lipinski MJ, Luger D, Waksman R, Bonow RO, Wu E, Epstein SE. Inflammation as a driver of adverse left ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol 2016;67:2050-60.CrossRef

Ong SB, Hernandez-Resendiz S, Crespo-Avilan GE, Mukhametshina RT, Kwek XY, Cabrera-Fuentes HA, Hausenloy DJ. Inflammation following acute myocardial infarction: Multiple players, dynamic roles, and novel therapeutic opportunities. Pharmacol Ther 2018;186:73-87.CrossRef

Shimamoto A, Chong AJ, Yada M, Shomura S, Takayama H, Fleisig AJ, Agnew ML, Hampton CR, Rothnie CL, Spring DJ, Pohlman TH, Shimpo H, Verrier ED. Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury. Circulation 2006;114:I270-4.CrossRef

Shishido T, Nozaki N, Yamaguchi S, Shibata Y, Nitobe J, Miyamoto T, Takahashi H, Arimoto T, Maeda K, Yamakawa M, Takeuchi O, Akira S, Takeishi Y, Kubota I. Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation 2003;108:2905-10.CrossRef

10.

Toldo S, Abbate A. The NLRP3 inflammasome in acute myocardial infarction. Nat Rev Cardiol 2018;15:203-14.CrossRef

11.

Ruparelia N, Chai JT, Fisher EA, Choudhury RP. Inflammatory processes in cardiovascular disease: A route to targeted therapies. Nat Rev Cardiol 2017;14:133-44.CrossRef

12.

Coll RC, Robertson AA, Chae JJ, Higgins SC, Munoz-Planillo R, Inserra MC, Vetter I, Dungan LS, Monks BG, Stutz A, Croker DE, Butler MS, Haneklaus M, Sutton CE, Nunez G, Latz E, Kastner DL, Mills KH, Masters SL, Schroder K, Cooper MA, O’Neill LA. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med 2015;21:248-55.CrossRef

13.

Coll RC, Hill JR, Day CJ, Zamoshnikova A, Boucher D, Massey NL, Chitty JL, Fraser JA, Jennings MP, Robertson AAB, Schroder K. MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition. Nat Chem Biol 2019;15:556-9.CrossRef

14.

Laliberte RE, Perregaux DG, Hoth LR, Rosner PJ, Jordan CK, Peese KM, Eggler JF, Dombroski MA, Geoghegan KF, Gabel CA. Glutathione S-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1 beta posttranslational processing. J Biol Chem 2003;278:16567-78.CrossRef

15.

Tapia-Abellan A, Angosto-Bazarra D, Martinez-Banaclocha H, de Torre-Minguela C, Ceron-Carrasco JP, Perez-Sanchez H, Arostegui JI, Pelegrin P. MCC950 closes the active conformation of NLRP3 to an inactive state. Nat Chem Biol 2019;15:560-4.CrossRef

16.

Gao R, Shi H, Chang S, Gao Y, Li X, Lv C, Yang H, Xiang H, Yang J, Xu L, Tang Y. The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction. Int Immunopharmacol 2019;74:105575.CrossRef

17.

van Hout GP, Bosch L, Ellenbroek GH, de Haan JJ, van Solinge WW, Cooper MA, Arslan F, de Jager SC, Robertson AA, Pasterkamp G, Hoefer IE. The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction. Eur Heart J 2017;38:828-36.PubMed

18.

Frantz S, Nahrendorf M. Cardiac macrophages and their role in ischaemic heart disease. Cardiovasc Res 2014;102:240-8.CrossRef

19.

Nahrendorf M, Swirski FK. Abandoning M1/M2 for a network model of macrophage function. Circ Res 2016;119:414-7.CrossRef

20.

Osborne MT, Hulten EA, Murthy VL, Skali H, Taqueti VR, Dorbala S, DiCarli MF, Blankstein R. Patient preparation for cardiac fluorine-18 fluorodeoxyglucose positron emission tomography imaging of inflammation. J Nucl Cardiol 2017;24:86-99.CrossRef

21.

Alvi RM, Young BD, Shahab Z, Pan H, Winkler J, Herzog E, Miller EJ. Repeatability and optimization of FDG positron emission tomography for evaluation of cardiac sarcoidosis. JACC Cardiovasc Imaging 2019;12:1284-7.CrossRef

22.

Abraham A, Nichol G, Williams KA, Guo A, deKemp RA, Garrard L, Davies RA, Duchesne L, Haddad H, Chow B, DaSilva J, Beanlands RS, Investigators P. 18F-FDG PET imaging of myocardial viability in an experienced center with access to 18F-FDG and integration with clinical management teams: The Ottawa-FIVE substudy of the PARR 2 trial. J Nucl Med 2010;51:567-74.CrossRef

23.

Henkel DM, Witt BJ, Gersh BJ, Jacobsen SJ, Weston SA, Meverden RA, Roger VL. Ventricular arrhythmias after acute myocardial infarction: A 20-year community study. Am Heart J 2006;151:806-12.CrossRef

24.

Gorenek B, Lundqvist CB, Terradellas JB, Camm AJ, Hindricks G, Huber K, Kirchhof P, Kuck KH, Kudaiberdieva G, Lin T, Raviele A, Santini M, Tilz RR, Valgimigli M, Vos MA, Vrints C, Zeymer U. Cardiac arrhythmias in acute coronary syndromes: Position paper from the joint EHRA, ACCA, and EAPCI task force. Eur Heart J Acute Cardiovasc Care 2015;4:386.CrossRef

25.

Prabhu SD, Frangogiannis NG. The biological basis for cardiac repair after myocardial infarction: From inflammation to fibrosis. Circ Res 2016;119:91-112.CrossRef

26.

Frangogiannis NG. The extracellular matrix in ischemic and nonischemic heart failure. Circ Res 2019;125:117-46.CrossRef

27.

Frangogiannis NG. Can myocardial fibrosis be reversed? J Am Coll Cardiol 2019;73:2283-5.CrossRef

Titel: 18F-FDG PET imaging of myocardial inflammation and viability following experimental infarction and anti-inflammatory treatment with compound MCC950
verfasst von: Jeremy Jong, BS
René R. Sevag Packard, MD, PhD
Publikationsdatum: 24.04.2020
Verlag: Springer International Publishing
Erschienen in: Journal of Nuclear Cardiology / Ausgabe 5/2021
Print ISSN: 1071-3581
Elektronische ISSN: 1532-6551
DOI: https://doi.org/10.1007/s12350-020-02104-5

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2021

18F-FDG PET/CT identifying cardiac abscess formation prior to cardiac CT

Myocardial perfusion years after radiation therapy for left-sided breast cancer: Normal or abnormal? This is the question

Reproducibility and repeatability of assessment of myocardial light chain amyloidosis burden using 18F-florbetapir PET/CT

Rise and fall, and provisional rebirth of exercise stress testing at the dawn of the third millennium

18F-sodium fluoride and vascular calcification: Some like it hot